Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

In the latest quarter, 15 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing ...

BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

BioNTech (NASDAQ: BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...

LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence ...

Atomi Financial Group Inc. bought a new position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) during the 3rd quarter, ...

Truist Financial Corp lowered its position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 4.1% in the second quarter ...

Pfizer (NYSE: PFE) was a stock on the move Wednesday, and not because of any news generated by the healthcare company. Reports of a meeting between Pfizer's leader and an activist investor ...

Shares of NASDAQ BNTX opened at $117.47 on Monday. The business has a 50-day simple moving average of $99.38 and a two-hundred day simple moving average of $92.98. BioNTech has a 52 week low of ...